Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05130255 · ClinicalTrials.gov registry record · Phase 1
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
A Phase 1 study of Sarcoma and Malignant Melanoma, sponsored by Y-mAbs Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT05130255: Recruiting Phase 1 study of Sarcoma and Malignant Melanoma, sponsored by Y-mAbs Therapeutics.
NCT05130255 is a Phase 1 study of Sarcoma and Malignant Melanoma that is actively recruiting participants, run by Y-mAbs Therapeutics. The registered enrollment target is 60 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05130255, a Phase 1 study of Sarcoma and Malignant Melanoma, is actively recruiting participants, sponsored by Y-mAbs Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Primary Outcome
Adverse events meeting the criteria of a dose limiting toxicity are graded according to CTCAE version 5
Conditions Studied
Interventions
- DRUG GD2-SADA:177Lu-DOTA Complex
Study Locations (8)
Arizona
- HonorHealth - Scottsdale
California
- City of Hope National Medical Center - Duarte
Illinois
- University of Chicago - Chicago
Michigan
- Corewell Health-BAMF Health - Grand Rapids
New York
- Memorial Sloan- Kettering Cancer Center - New York
Ohio
- Case Western Reserve University, Cleveland - Cleveland
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Wisconsin
- University of Wisconsin-Madison - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-11-17 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT05130255 shows while recruiting
NCT05130255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which GD2-SADA:177Lu-DOTA Complex is the first listed.
NCT05130255 lists 8 locations in 8 states (Arizona, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT05130255 about?
NCT05130255 is a clinical study titled "GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2". Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
What is the current status of trial NCT05130255?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2022-11-17. Estimated completion is 2027-04.
What conditions does trial NCT05130255 study?
This clinical trial studies the following conditions: Sarcoma, Malignant Melanoma, SCLC, High-risk Neuroblastoma.
What interventions are being tested in trial NCT05130255?
The interventions under investigation include: GD2-SADA:177Lu-DOTA Complex (DRUG).
Who is sponsoring clinical trial NCT05130255?
This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05130255 being conducted?
This trial has 8 study locations across Arizona, California, Illinois, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05130255's enrollment target sits among peer trials
60 60th of 122 higher than 60 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy